• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Bromobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Bromobenzenes

Recent Advances in the Study of (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine (CAS: 843608-54-8)

In recent years, (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine (CAS: 843608-54-8) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This chiral amine, characterized by its trifluoroethyl and bromophenyl substituents, has shown promising potential in various therapeutic applications, particularly in the development of novel central nervous system (CNS) agents and enzyme inhibitors. The unique structural features of this compound, including its stereochemistry and halogenated aromatic ring, contribute to its biological activity and make it a valuable scaffold for drug discovery.

Recent studies have focused on the synthesis and optimization of (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine to enhance its pharmacological properties. A 2023 publication in the Journal of Medicinal Chemistry reported an improved asymmetric synthesis route for this compound, achieving higher enantiomeric purity and yield. The researchers utilized a chiral auxiliary approach, which allowed for better control over the stereocenter and reduced the formation of undesired byproducts. This advancement is critical for scaling up production and ensuring the consistency of the compound for further biological evaluations.

The pharmacological profile of (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine has been extensively investigated in preclinical models. A study published in Bioorganic & Medicinal Chemistry Letters demonstrated its potent inhibitory activity against monoamine oxidase B (MAO-B), an enzyme implicated in neurodegenerative disorders such as Parkinson's disease. The compound exhibited a high selectivity for MAO-B over MAO-A, with an IC50 value in the nanomolar range. This selectivity is attributed to the optimal positioning of the bromophenyl group within the enzyme's active site, as revealed by molecular docking simulations.

In addition to its MAO-B inhibitory activity, (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine has shown promise as a modulator of sigma-1 receptors, which play a role in neuroprotection and cognitive function. A 2022 study in Neuropharmacology reported that the compound exhibited significant affinity for sigma-1 receptors and demonstrated neuroprotective effects in an in vitro model of oxidative stress. These findings suggest its potential utility in treating neurodegenerative and psychiatric conditions, although further in vivo studies are needed to validate these effects.

Another area of interest is the application of (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine in the development of radiolabeled probes for imaging studies. Researchers have explored its use as a precursor for fluorine-18 labeled tracers, leveraging the presence of the trifluoroethyl group. A recent study in the Journal of Labelled Compounds and Radiopharmaceuticals described the successful radiosynthesis of a fluorine-18 derivative, which exhibited favorable pharmacokinetics and brain uptake in preliminary PET imaging experiments. This advancement opens new avenues for non-invasive imaging of CNS targets.

Despite these promising developments, challenges remain in the clinical translation of (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine. Issues such as metabolic stability, bioavailability, and potential off-target effects need to be addressed through further structural optimization and comprehensive toxicological studies. Ongoing research aims to explore derivatives and prodrugs of this compound to overcome these limitations while retaining its desirable pharmacological properties.

In conclusion, (1R)-1-(3-Bromophenyl)-2,2,2-trifluoroethylamine (CAS: 843608-54-8) represents a versatile and pharmacologically active scaffold with significant potential in drug discovery and imaging applications. Recent advances in its synthesis, mechanistic understanding, and therapeutic applications underscore its importance in chemical biology and medicinal chemistry. Continued research efforts are expected to further elucidate its full therapeutic potential and pave the way for its clinical development.

• 842169-72-6(1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine hydrochloride)
• 843608-46-8(1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine)
• 878539-31-2((S)-1-(3-Bromophenyl)-2,2,2-trifluoroethanamine)
• 336105-43-2((s)-1-(4-Bromophenyl)-2,2,2-trifluoroethanamine Hydrochloride)
• 843608-53-7((1R)-1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine)
• 778565-93-8((1S)-1-(4-bromophenyl)-2,2,2-trifluoroethan-1-amine)
• 842169-71-5(1-(3-Bromo-phenyl)-2,2,2-trifluoro-ethylamine hydrochloride)
• 842169-83-9((R)-1-(4-Bromophenyl)-2,2,2-trifluoroethanamine hydrochloride)
• 1270402-57-7(1-(4-bromo-2-methylphenyl)-2,2,2-trifluoroethanamine)
• 878408-46-9((s)-1-(3-Bromophenyl)-2,2,2-trifluoroethan-1-amine Hydrochloride Salt)